Decision Diagnostics (DECN) Falls Despite Rising GenViro! Sales

The fascinating Decision Diagnostics (OTC: DECN) supposed to soar more than $1 as quickly as announcing new purchase orders for its GenViro! saliva test kits. Many traders still expect a higher rise from DECN as it is aiding a significant number of countries with COVID-19 test kits but full attention is turned to green tech stocks as Joe Biden wins the election. Trump’s presidency has been backing the coronavirus stocks with financial rewards and endorsements.

Certainly, on Monday healthcare stocks will likely rise again if Biden focuses on solving the pandemic issues with top health experts. Maybe Antony Fauci will discuss with the 46th U.S president. DECN will sharply grow after those meetings. Triumphal July’s prices may be shown on screen after the stock skyrockets.

Related:  Growing Stock To Consider: Co-Diagnostics Inc (NasdaqGS: CODX)

Since March DECN has been in the center of talks on forums like StockTwits and InvestorHub that usually predict the future demand for the shares sold in major markets. Surprisingly, the stock shouldn’t be falling early before Biden’s arrival to power because even one sentence can push most stocks significantly.

Jack Dawkins

Finance and Tech Contributor